Fmr LLC Grows Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN)

FMR LLC grew its position in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 922.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 828,665 shares of the company's stock after buying an additional 747,649 shares during the quarter. FMR LLC owned 1.46% of Design Therapeutics worth $4,458,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. The Manufacturers Life Insurance Company purchased a new stake in shares of Design Therapeutics in the 3rd quarter worth $71,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Design Therapeutics by 43.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 257,432 shares of the company's stock worth $1,385,000 after purchasing an additional 77,472 shares during the last quarter. Palumbo Wealth Management LLC lifted its stake in shares of Design Therapeutics by 11.3% during the 3rd quarter. Palumbo Wealth Management LLC now owns 36,774 shares of the company's stock worth $198,000 after purchasing an additional 3,720 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Design Therapeutics during the 3rd quarter worth $66,000. Finally, Cubist Systematic Strategies LLC lifted its stake in shares of Design Therapeutics by 75.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 23,497 shares of the company's stock worth $79,000 after purchasing an additional 10,113 shares during the last quarter. 56.64% of the stock is currently owned by hedge funds and other institutional investors.

Design Therapeutics Stock Down 8.8 %

Shares of NASDAQ DSGN traded down $0.54 during mid-day trading on Friday, reaching $5.60. 281,657 shares of the company were exchanged, compared to its average volume of 234,965. The stock has a market cap of $317.08 million, a price-to-earnings ratio of -6.59 and a beta of 1.86. Design Therapeutics, Inc. has a 1 year low of $2.24 and a 1 year high of $7.77. The firm has a 50-day moving average of $5.76 and a 200 day moving average of $4.91.

Design Therapeutics Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.